PARP inhibitors also synergize with the pan-CDK inhibitor dinaciclib in reducing MYC expression in TNBC and other cancer types, resulting in down-regulation of HR genes and induction of DNA damage (Carey et al. 2018). Here, PARP1 is linked to cancer.